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Respiratory dysfunction has been associated with Parkinson’s disease since 
it was first described in 1817. The respiratory symptoms observed in 
Parkinson’s disease patients vary greatly. Most patients remain 
asymptomatic, whereas others present with acute shortness of breath and 
even stridor. 
In August 2016, an electronic literature search was conducted using PubMed and Google 
Scholar. Results were screened and studies reporting on respiratory dysfunction associated 
with Parkinson’s disease were included.
Respiratory dysfunction is due to a combination of factors including restrictive changes, upper 
airway obstruction, abnormal ventilatory drive and response to medications. 
Much debate surrounds the mechanism underlying respiratory dysfunction in Parkinson’s 
disease, its prevalence and the effect of levodopa on respiration. It is clear from this review 
that larger studies, comparing patients of similar disease duration and severity using the 
same pulmonary function parameters, are required to provide a better understanding of the 
pathophysiology underlying respiratory dysfunction in Parkinson’s disease.
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Introduction
Parkinson’s disease (Pd) is a common progressive 
neurodegenerative disorder associated with tremor, rigidity, 
bradykinesia and postural instability. These abnormalities 
are not limited to the extremities but also affect the striated 
muscle within the upper airways and chest wall. respiratory 
dysfunction has been associated with Pd since James 
Parkinson ﬁ rst described it in 1817,1 and it remains one of 
the most common causes of death in these patients. 
Patients with Pd may present with a variety of respiratory 
symptoms ranging from dyspnoea without any overt clinical 
evidence of respiratory dysfunction, exertional dyspnoea, 
daytime somnolence due to nocturnal hypoxia and acute 
stridor. The majority, however, remain asymptomatic even 
with grossly abnormal pulmonary function tests.2 This may 
be due to the motor manifestations of their Pd limiting their 
exercise tolerance; it may also be due to the heterogeneous 
nature of Pd and how it affects each patient differently. 
shortness of breath in Pd can be very distressing for patients 
and clinicians alike. extensive investigations are carried 
out, often repeatedly during recurrent admissions, looking 
for infection, pulmonary emboli, heart failure and anxiety. 
although these are possible in Pd patients and should be 
excluded, clinicians must remember that Pd itself and its 
medications can lead to shortness of breath through various 
mechanisms. efﬁ cient ventilation depends on several factors 
including adequate airways, sufﬁ cient respiratory muscular 
function and a chemoreceptor drive to breathing. 
Pd can affect each of these to a varying degree. several 
patterns of respiratory dysfunction have been described in Pd, 
including: restrictive changes secondary to chest wall rigidity 
and reduction in lung volume secondary to kyphoscoliosis, 
upper airway obstruction, abnormal ventilatory control, 
diaphragmatic dyskinesias and pleuropulmonary complications 
of medications. in addition, although rare, shortness of breath 
is an important non-motor wearing off symptom. 
There is controversy as to whether levodopa improves or 
worsens respiratory function. This review will not cover in 
detail the respiratory complications of Pd but rather look at 
the spectrum of respiratory dysfunction in Pd as well as the 
effects of levodopa on pulmonary function tests. 
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Search strategy 
an electronic literature search was conducted in august 2016, 
using Pubmed and google scholar. The following search term 
were used: ‘Parkinson’s disease’ combined with the boolean 
operator ‘and’ and each of the following terms: ‘respiratory 
disorder’; ‘respiratory dysfunction’; ‘pulmonary disorder’; 
‘pulmonary dysfunction’. after duplicates were removed, the 
titles were initially scanned and abstracts of interest were 
reviewed. only articles in the english language were included. 
The reference lists of all relevant articles were hand-searched 
for additional suitable articles.
studies were included if they studied respiratory dysfunction 
in Pd. studies were excluded if they included the following 
criteria: (a) respiratory complications of Pd; (b) animal 
studies; (c) neurological disorders other than Pd, e.g. 
multi-system atrophy, dystonia, multiple sclerosis; and (d) 
conference abstracts. The literature search yielded 49 non-
duplicated articles, of which 23 were suitable. after hand-
searching the reference lists, a further two were included. 
The studies were undertaken between 1966 and 2016, and 
included small numbers of patients ranging from 12 to 78. 
Findings
Upper airway obstruction
upper airway obstruction (uao) has been reported in over 33% 
of Pd patients.2,3 The most common and frequently reported 
manifestation of upper airway dysfunction is hypophonia, 
which affects up to 70% of patients.4 other potential features 
include ‘shaky’ voice, wheeze, and stridor.
Two other types of uao have been described; both are often 
asymptomatic.3 Prior to this classiﬁ cation, there was no 
general consensus as to the cause or site of obstruction. 
The ﬁ rst type of uao, also referred to as ‘respiratory ﬂ utter’, 
is characterised by uao with superimposed rapid oscillations 
of the supraglottic structures and vocal cords, which are 
apparent on ﬂ ow volume loops generated by spirometry 
measurements. on direct ﬁ breoptic visualisation, these 
oscillations correspond to the rhythmic 4–8 hz resting 
tremor seen in Pd patients. vincken et al.3 reported this to 
be present in 78% of their cohort and it is thought to be due 
to basal ganglia dysfunction. 
The second type of uao is characterised by irregular abrupt 
changes in the ﬂ ow volume loop, which at times leads to 
complete obstruction. There is rounding off of the expiratory 
phase and a delayed peak. This was thought to be less 
common than the ﬁ rst type, occurring in only 22% of patients. 
however a more recent study2 reported this as the most 
common type, observed in 82% of their cohort. This may 
be explained by the fact that a higher proportion of patients 
included in the ﬁ rst study had a peripheral tremor.3
The prevalence of uao in Pd patients ranges from 6.7% 
to 67%.5,6 The differences in rates reported depended on 
whether levodopa was administered during the study or 
whether it was withheld. 
in those patients whose levodopa was withheld, uao was 
associated with abnormal inspiratory and expiratory ﬂ ow rates 
in 62% of patients6 consistent with older reports.7,8 however, 
these older studies included patients with Parkinsonism and 
post-encephalitic Parkinsonism.
lower rates of obstructive respiratory dysfunction were 
observed when levodopa was continued.5,9 This suggests uao 
may be sensitive to levodopa. additional evidence for the 
positive effect of levodopa on uao comes from reports of uao 
with stridor and respiratory failure occurring when levodopa is 
stopped.4 This is important to consider, especially in acutely 
unwell patients and those in the peri-operative period. 
There is limited research looking at the relationship between 
uao and other symptoms associated with Pd. uao has 
been observed in patients with a higher degree of rigidity, 
bradykinesia6 and tremor.8 a recent case-control study 
showed a negative correlation between uao and the patient’s 
age.10 uao has also been associated with a higher degree 
of dorsal column arthrosis, most likely due to restriction in 
movement.6 Pulmonary function tests are not only limited by 
cervical restriction but also affected by thoraco-abdominal 
movements. in patients with Pd, a reduction in percentage 
vital capacity correlates with chest movements, and a 
reduction in percentage forced vital capacity (fvc) correlates 
with abdominal movements.11
The overall prevalence of uao appears to be diminishing in Pd 
patients. This may reﬂ ect the increasing diagnostic accuracy 
of uao and its management or it may reﬂ ect a therapeutic 
effect of levodopa.5 it may also reﬂ ect the types of patients 
studied. earlier studies investigating respiratory dysfunction 
in Pd included patients who were post encephalopathic, 
smokers, ex-smokers and patients with chronic obstructive 
pulmonary disease, which may bias their results.
Restrictive respiratory dysfunction
The mechanisms underlying the restrictive pattern of 
respiratory dysfunction observed in Pd patients are not 
fully understood. it is likely to result from a combination 
of factors including increased rigidity of the chest wall, a 
theory supported by electromyographic studies of respiratory 
muscles12 which reveal abnormal activity throughout the 
respiratory cycle with a frequency similar to 4–8 hz; reduction 
in lung volume secondary to kyphoscoliosis leading to reduced 
ventilation; and pleuropulmonary changes secondary to long 
term ergot-derived dopamine agonist use. 
The frequency of restrictive respiratory dysfunction reported 
in Pd varies from 28%6 to 94%,13,14 depending on the cohort 
studied, the severity of the disease and whether patients 
were taking levodopa or not. Typical symptoms are those of 
exertional dyspnoea.
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since sabate et al. in 1996,6 higher incidences of restrictive 
respiratory disease have been observed in Pd patients13–15 
and a link between this and the motor manifestations of Pd 
has been described. a restrictive pattern has been shown to 
correlate with falls and freezing but not with tremor, rigidity 
or bradykinesia.6 There is also a correlation with a moderate 
decrease in dorsal extension of the cervical neck.6 however, 
other studies dispute this ﬁ nding. one reported a signiﬁ cant 
correlation between restrictive respiratory dysfunction and 
the severity of Pd, as well as, to a lesser extent, the duration 
of the disease.15 another reported rigidity and bradykinesia 
correlate with a restrictive pattern, especially in female Pd 
patients, but no link to tremor was noted.16
The effect of levodopa on restrictive respiratory disease is 
controversial. some authors have shown an improvement 
in respiratory function after levodopa13,14,16 whereas others 
did not.17 These discrepancies may be due to differences 
in the patient’s age, disease duration and severity and 
techniques used to assess respiratory function as well as 
the parameters measured. 
Abnormal central control of ventilation
dyspnoea in Pd can occur through both a central and peripheral 
mechanism. it is deﬁ ned by the american lung association as 
a ‘subjective experience of breathing discomfort that derives 
from interactions among multiple physiological, psychological, 
social and environmental factors’.18 
as discussed, many patients have respiratory dysfunction; 
yet the majority remain asymptomatic and do not report 
dyspnoea. The reason for this may be twofold. first, as the 
disease progresses, the motor manifestations of Pd limit a 
patient’s exercise tolerance and so respiratory problems may 
not manifest themselves. second, Pd patients have been 
shown to have an impaired perception of dyspnoea (Pod). 
Those who report dyspnoea with no objective evidence of 
respiratory dysfunction are often mistakenly diagnosed as 
anxious or depressed. an increased and a decreased Pod 
have been reported in Pd patients.17,19 an impaired Pod 
may be due to peripheral factors, e.g. muscle weakness, 
restrictive respiratory pattern or uao, or it may be due to an 
abnormal respiratory drive. 
normally the respiratory drive is inﬂ uenced by hypercapnia. 
however, in Pd there is a reduced response to carbon 
dioxide.20 This abnormality of central ventilatory control may be 
explained, in part, by the braak hypothesis,21 which suggests 
there is early brainstem involvement in Pd with selective 
degeneration of the dopaminergic cells in the medulla.3,17 The 
carotid body is highly dopaminergic and plays a role in the 
ventilatory response to hypoxia. seccombe et al.20 did not ﬁ nd 
an abnormal response to mild hypoxia, contradicting previous 
studies that showed patients in the early stages of Pd to 
have a subnormal response to hypoxia,19, 22 in addition to a 
reduced Pod and a normal response to hypercapnia.19 The 
mild hypoxia challenge used in the ﬁ rst study may account 
for the lack of response seen.
The reduced Pod reported is not consistent with a more recent 
study,23 which showed Pd patients to have a heightened Pod 
that decreased signiﬁ cantly after levodopa administration, 
yet still remained higher than normal subjects. The patients 
studied may explain this increased Pod reported, as in 
contrast to the ﬁ rst paper,19 they had longstanding Pd and 
had abnormal pulmonary function tests. Thus, mechanical 
ventilatory factors may have contributed to the increased 
Pod they reported. 
levodopa leads to a signiﬁ cant improvement in Pod without 
an improvement in pulmonary function tests, suggesting that 
levodopa is acting centrally.17,20 There is a paucity of evidence 
for investigations into brainstem-mediated function in these 
patients; however, it seems plausible that as Pd progresses 
with further loss of dopaminergic cells in the midbrain and 
basal ganglia, there is also further loss in the medulla, thus 
leading to a worsening of respiratory function and ventilation. 
in addition to levodopa, speciﬁ c inspiratory muscle training 
has been shown to decrease Pod by improving inspiratory 
muscle strength and endurance. despite this, there was no 
associated improvement in quality of life assessed using 
questionnaires.22
Drugs and respiratory dysfunction
levodopa is the gold standard treatment for Pd, but its 
effects on respiratory function are not clear. There are reports 
that levodopa improves both uao and restrictive respiratory 
dysfunction,2,9,13,16 has no effect7 or even worsens respiratory 
function.17,24 one study demonstrated an improvement in 
respiratory musculature and pulmonary function tests 
following apomorphine.25
The differences reported in these studies may be accounted 
for by the number of patients studied, disease duration 
and severity, and the severity of the respiratory disease. 
as Pd progresses, levodopa becomes less efficacious. 
respiratory dysfunction has been shown to worsen as 
disease progresses4 and one wonders whether respiratory 
dysfunction also becomes less responsive to levodopa?
Upper airways obstruction
levodopa has been shown to induce signiﬁ cant variations 
in peak expiratory ﬂ ow and uao ratios with a reduction in 
uao.9,26 it has also been linked to an increase in total lung 
capacity;26 however, a more recent study showed no increase 
in total lung capacity.9 obenour et al.7 found no change in 
pulmonary function tests following levodopa administration 
and lim et al.27 actually found an improvement in fvc 
and forced expiratory volume in one second (fev1) when 
levodopa was stopped. however, it must be noted that 
these changes were small and did not reach statistical 
signiﬁ cance.27
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Restrictive respiratory dysfunction
a meta-analysis, consisting of four trials with 73 patients in 
total, concluded levodopa improved fvc and peak expiratory 
ﬂ ow but had no effect on fev1 and the fev1/fvc ratio.28 
Side effects of Parkinson’s disease medications
levodopa and ergot-derived dopamine agonists may also 
induce respiratory dysfunction in Pd. levodopa-induced 
diaphragmatic dyskinesias may lead to rapid strenuous and 
distressful dyspnoea.29,30 additionally, dyspnoea may also 
occur as a wearing off phenomenon in Pd patients taking 
levodopa. Pleuropulmonary ﬁ brosis and pleural effusions 
have been reported in patients taking ergot-derived dopamine 
agonists. it usually develops within three years of starting 
these medications, although it has been reported in a patient 
after 11 years.31 
Conclusion
respiratory dysfunction remains the most common cause 
of death in patients with Pd. There are several possible 
mechanisms for the respiratory dysfunction observed in Pd 
patients and it is likely to be due to a combination of these.
The prevalence of both obstructive and restrictive pulmonary 
dysfunction varies greatly between studies. The discrepancies 
noted can be explained by the number of patients studied (as 
very small numbers were included in each publication); the 
past medical history of the patients included; the pulmonary 
function test parameters used; and whether levodopa was 
held or continued during the study. it may also be explained 
by the heterogeneous nature of Pd itself. 
The role of levodopa in respiratory dysfunction is controversial. 
only one meta-analysis including four studies was found in 
our search. more studies are required with larger numbers 
of patients to conclusively ascertain its effects on both 
obstructive and restrictive respiratory dysfunction in Pd 
and to investigate whether it is worth considering starting 
levodopa early in these patients in order to prevent further 
progression of their respiratory dysfunction.
greater awareness of respiratory dysfunction in Pd may 
better equip clinicians to identify signs and symptoms earlier, 
thus avoiding extensive unnecessary investigations but also 
preventing complications. it may also prompt clinicians to 
ask about respiratory symptoms in Pd patients, leading 
to appropriate investigations being conducted early on. 
currently there is no evidence base for conducting pulmonary 
function tests in asymptomatic patients. yet we know 
the majority remain asymptomatic, even with profoundly 
abnormal pulmonary function tests. To help clinicians identify 
those who should be investigated, it would be useful if 
studies were carried out that looked at whether investigating 
asymptomatic patients is feasible and valid. There is strong 
evidence that longitudinal spirometry measurements of 
acceptable quality can be obtained in patients with Pd, even 
when motor ﬂ uctuations are present32 and it would also allow 
clinicians to monitor progress during treatment and exercise 
programmes.
it is of vital importance that more systematic studies are 
conducted to investigate respiratory dysfunction in Pd, as 
well as the effect of levodopa on respiratory dysfunction, 
respiratory muscle strength and its effect on central 
ventilatory control. 
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